Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 54 for:    prevail therapeutics
Previous Study | Return to List | Next Study

Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04408625
Recruitment Status : Recruiting
First Posted : May 29, 2020
Last Update Posted : May 17, 2021
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Prevail Therapeutics

Brief Summary:
Study PRV-FTD101 is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal PR006 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Three escalating dose (low dose, medium dose and high dose) cohorts are planned. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of PR006 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

Condition or disease Intervention/treatment Phase
Frontotemporal Dementia Biological: PR006 Drug: Methylprednisolone Drug: Sirolimus Drug: Prednisone Drug: Rituximab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)
Actual Study Start Date : November 9, 2020
Estimated Primary Completion Date : September 2027
Estimated Study Completion Date : September 2027


Arm Intervention/treatment
Experimental: Low dose Biological: PR006
Participants will receive a single dose of PR006, administered intra cisterna magna

Drug: Methylprednisolone
1-2 IV pulses administered as concomitant medication

Drug: Sirolimus
Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Drug: Prednisone
Administered orally as concomitant medication, followed by dose tapering.

Drug: Rituximab
Single IV pulse administered as concomitant medication.

Experimental: Medium dose Biological: PR006
Participants will receive a single dose of PR006, administered intra cisterna magna

Drug: Methylprednisolone
1-2 IV pulses administered as concomitant medication

Drug: Sirolimus
Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Drug: Prednisone
Administered orally as concomitant medication, followed by dose tapering.

Drug: Rituximab
Single IV pulse administered as concomitant medication.

Experimental: High dose Biological: PR006
Participants will receive a single dose of PR006, administered intra cisterna magna

Drug: Methylprednisolone
1-2 IV pulses administered as concomitant medication

Drug: Sirolimus
Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Drug: Prednisone
Administered orally as concomitant medication, followed by dose tapering.

Drug: Rituximab
Single IV pulse administered as concomitant medication.




Primary Outcome Measures :
  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation [ Time Frame: Year 5 ]
  2. Sum of adverse reactions (ARs) and suspected ARs [ Time Frame: 5 years ]
  3. Sum of serious ARs and serious suspected ARs [ Time Frame: 5 years ]
  4. Incidence of procedure or treatment-emergent AEs [ Time Frame: 5 years ]
    Measured by brain and spine MRI

  5. Change in PGRN immunogenicity in blood [ Time Frame: Baseline and 12 months ]
    PGRN: progranulin protein. Measured by level of antibodies and ELISPOT

  6. Change in PGRN immunogenicity in CSF [ Time Frame: Baseline and 12 months ]
    CSF: cerebrospinal fluid

  7. Change in AAV9 immunogenicity in blood [ Time Frame: Baseline and 12 months ]
    Measured by level of antibodies and ELISPOT.

  8. Change in AAV9 immunogenicity in CSF [ Time Frame: Baseline and 12 months ]
    Measured by levels of antibodies.

  9. Change in PGRN levels in blood [ Time Frame: Baseline and 12 months ]
  10. Change in PGRN levels in CSF [ Time Frame: Baseline and 12 months ]

Secondary Outcome Measures :
  1. Change in CDR plus NACC FTLD [ Time Frame: Baseline and 12 months ]
    CDR: Clinical Dementia Rating staging instrument. NACC FTLD: National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains

  2. Change in NfL levels in blood [ Time Frame: Baseline and 12 months ]
    NfL: neurofilament light chain

  3. Change in NfL levels in CSF [ Time Frame: Baseline and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lb) and a BMI of 18 to 34 kg/m2.
  • Has symptomatic frontotemporal dementia (FTD) per investigator assessment.
  • Stable use of background medications at least 8 weeks prior to PR006A dosing.
  • Carrier of a pathogenic GRN (progranulin gene) mutation.
  • Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1 year prior to screening.
  • Age- and gender-appropriate cancer screenings are up-to-date.
  • Patient and/or patient's legally authorized representative has the ability to understand the purpose and risks of the study, and provide written informed consent and authorization to use protected health information.
  • Patient has a reliable study partner/informant (e.g. family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities.
  • Patient is not dependent on a walker or wheelchair.
  • Patient is living in the community (i.e. not in nursing home); some levels of assisted living may be permitted at the discretion of the investigator.
  • Pneumococcal pneumonia and shingles vaccines are required within 10 years of Screening (allowed to be performed during Screening but must be given at least 4 weeks prior to initiation of immunosuppressant regimen).

Exclusion Criteria:

  • Diagnosis of a significant CNS (central nervous system) disease other than frontotemporal dementia (FTD) that may cause FTD symptoms or confound study objectives.
  • Brain or cervical magnetic resonance image (MRI)/MRA imaging showing clinically significant abnormality considered to prevent intracisternal injection.
  • Hypersensitivity or contraindications to corticosteroid, rituximab, and/or sirolimus use.
  • Clinical evidence of peripheral symmetric sensory polyneuropathy (stable sensory mononeuropathies and radiculopathies are not exclusionary).
  • Concomitant disease or condition within 6 months of screening that could interfere with, or treatment of which might interfere with, the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the patient or interfere with the patient's ability to comply with study procedures
  • Clinically significant laboratory test result abnormalities assessed at screening.
  • Participation within 3 months prior to screening in another therapeutic investigational drug or device study with purported disease-modifying effects on FTD, unless it can be documented that the patient received placebo only.
  • Any type of prior gene or cell therapy.
  • Immunizations (live vaccines) in the 4 weeks prior to Screening. Pneumococcal vaccine and/or shingles vaccine administration is allowed at least 4 weeks prior to initiation of immunosuppressant regimen.
  • Use of blood thinners in the 2 weeks prior to screening, or anticipated use of blood thinners during the study. Antiplatelet therapies may be acceptable as long as usage can be halted 48 hours before study drug administration.
  • Contraindications or intolerance to imaging methods (MRA, MRI, CT) and intolerance to contrast agents.
  • Contraindications to general anesthesia or deep sedation.

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04408625


Contacts
Layout table for location contacts
Contact: Prevail Therapeutics (917) 336-9310 patients@prevailtherapeutics.com

Locations
Layout table for location information
United States, Florida
Bioclinica Orlando, 100 West Gore Street, Suite 202 Recruiting
Orlando, Florida, United States, 32806
Contact: Jessica Garaycoa    689-216-3100    Jessica.Garaycoa@ppdi.com   
Australia, New South Wales
Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street Recruiting
Camperdown, New South Wales, Australia, 2050
Contact: Cassandra Kaizik    02 9515 4540    cassandra.kaizik@sydney.edu.au   
Sponsors and Collaborators
Prevail Therapeutics
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Olga Uspenskaya-Cadoz, MD, PhD Prevail Therapeutics
Layout table for additonal information
Responsible Party: Prevail Therapeutics
ClinicalTrials.gov Identifier: NCT04408625    
Other Study ID Numbers: PRV-FTD101
First Posted: May 29, 2020    Key Record Dates
Last Update Posted: May 17, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Prevail Therapeutics:
Fronto-Temporal Dementia
Frontotemporal Dementia
Progranulin Mutations
FTD-GRN
Gene Therapy
Dementia Gene Therapy
AAV9
Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Aphasia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Sirolimus
Prednisone
Methylprednisolone
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Anti-Inflammatory Agents